Is BPC-157 Legal in Michigan? Federal Rules, State Law, and How to Get It

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. Preclinical data suggest it accelerates healing in tendons, ligaments, and gut tissue, but no Phase III human trial has produced an FDA-approved indication. That gap between early science and regulatory approval is exactly what creates legal complexity for patients and prescribers.

The Difference Between "Not Approved" and "Illegal"

"Not FDA-approved" does not equal "illegal." The Food, Drug, and Cosmetic Act (FD&C Act) prohibits the interstate sale of unapproved new drugs for human use, but it does not criminalize patient possession in the same way the Controlled Substances Act (CSA) does. BPC-157 has no CSA scheduling. Patients in Michigan who possess it are not committing a federal drug crime in the way a Schedule I substance holder would be.

The legal exposure comes from the supply chain, not from possession itself. Manufacturers who sell BPC-157 labeled "for human use" without FDA approval are violating the FD&C Act. FDA guidance on unapproved drugs lays out the agency's enforcement priorities for exactly this scenario. [1]

Why Preclinical Data Does Not Create Legal Access

Animal studies on BPC-157 are numerous. A 2021 review published in Biomedicines catalogued tendon and ligament repair findings across multiple rodent models. [2] Those results do not give pharmacies or prescribers a legal green light. The FDA requires controlled human trials before granting approval, and BPC-157 has not completed that pathway. Preclinical promise shapes clinical curiosity, not regulatory status.

Federal Regulatory Framework Governing BPC-157

Understanding the federal layer is essential before looking at Michigan-specific rules, because federal law preempts state law wherever both apply.

The FDA's Position on BPC-157 Specifically

The FDA does not list BPC-157 as an approved drug. It also does not appear on the agency's bulk drug substances list that permits 503A compounding pharmacies to use it without an individual patient prescription tied to a specific clinical need. The FDA's Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A, updated in guidance documents published on fda.gov, explains that a bulk substance must be nominated and evaluated before compounders may use it. [3] BPC-157 has been nominated but has not received a positive evaluation that would place it on the "Category 1" approved list.

That means compounding pharmacies operating under 503A are working in a gray zone when they prepare BPC-157. They are not categorically prohibited by a specific FDA order targeting BPC-157 alone, but they are not operating with explicit federal approval either.

503A vs. 503B: Two Different Compounding Pathways

These two sections of the FD&C Act govern different types of pharmacies, and the distinction matters for Michigan patients.

503A pharmacies are traditional state-licensed compounding pharmacies. They may prepare compounded drugs for individual patients when a licensed prescriber provides a valid prescription. They must use bulk substances from the FDA's approved list or substances that have not been specifically prohibited. The FDA's guidance on 503A compounding outlines the conditions clearly. [4] BPC-157's ambiguous bulk-substances status means 503A pharmacies face legal uncertainty, not an outright ban, when compounding it.

503B outsourcing facilities operate under stricter FDA oversight. They may produce larger batches for office stock without patient-specific prescriptions, but only using FDA-approved bulk substances. Because BPC-157 is not on that approved list, 503B facilities cannot legally compound it for general distribution. [5]

For Michigan patients, the practical takeaway: a 503A pharmacy with a valid prescription from a Michigan-licensed provider is the legally cleaner route. A 503B facility cannot supply it at all under current rules.

The FDA's 2023 and 2024 Peptide Enforcement Actions

The FDA issued Warning Letters to multiple peptide compounders in 2023 and 2024, citing unapproved new drug violations. Several of those letters specifically named peptides compounded without bulk-substance authorization. [6] The agency's Office of Pharmaceutical Quality has stated in public communications that it views the compounding of bulk peptides not on the approved list as a significant compliance risk. Those enforcement signals matter for Michigan pharmacies deciding whether to stock BPC-157.

Michigan State Law and the Board of Pharmacy

Michigan does not have a statute that names BPC-157 and declares it legal or illegal. State law operates by regulating the pharmacies, prescribers, and facilities that would supply it, rather than the molecule itself.

Michigan Public Health Code and Pharmacy Licensing

The Michigan Public Health Code, specifically MCL 333.17748, requires that compounding pharmacies operate under a license issued by the Michigan Board of Pharmacy (MBOP). The MBOP enforces compliance with both state standards and, by reference, federal USP compounding standards. [7] A Michigan pharmacy that compounds BPC-157 must follow USP Chapter 795 (non-sterile) or USP Chapter 797 (sterile) standards, as applicable.

BPC-157 for injection is a sterile preparation. That means the compounding pharmacy must meet the rigorous cleanroom, testing, and beyond-use dating requirements of USP 797. Pharmacies that lack proper 797 compliance risk state license action entirely separate from any FDA concern.

Prescriber Authority in Michigan

Michigan licenses physicians (MD, DO), nurse practitioners, and physician assistants to prescribe compounded preparations when a commercial alternative does not exist. BPC-157 has no FDA-approved commercial form, so a prescriber who writes for it is prescribing a compounded preparation, not an off-label approved drug. That is a meaningful legal distinction.

Prescribing a compounded preparation is legal in Michigan when the prescriber has a valid patient-provider relationship, documents the clinical rationale, and the preparation meets state and federal compounding requirements. [8] A prescriber who writes for BPC-157 is not automatically violating Michigan law, but they carry the professional burden of justifying the clinical decision under the Michigan Medical Practice Act, MCL 333.17001.

Does Michigan's Controlled Substances Act Cover BPC-157?

No. The Michigan Controlled Substances Act (MCL 333.7201 et seq.) schedules drugs based on federal CSA schedules and state-specific additions. BPC-157 is on neither list. It is not a controlled substance in Michigan. Possession by an individual patient is not a criminal act under state drug law. [9]

How Michigan Patients Can Legally Access BPC-157

The pathway with the least legal risk involves three steps: a licensed prescriber, a compliant compounding pharmacy, and a documented clinical rationale.

Step 1: Establish Care with a Licensed Michigan Prescriber

A telehealth provider or in-person clinic licensed in Michigan must evaluate the patient, document a clinical indication, and write a prescription. The prescription must name BPC-157 specifically, including the route (oral, subcutaneous injection, or topical), dose, and quantity. Telehealth prescribers licensed in Michigan may write this prescription provided they have an established patient relationship compliant with Michigan telehealth law under MCL 333.16285. [10]

Clinicians at practices like HealthRX, operating under physician oversight, can conduct this evaluation and prescribe when appropriate.

Step 2: Fill the Prescription at a 503A-Compliant Pharmacy

The patient's prescription goes to a 503A state-licensed compounding pharmacy. The pharmacy must source BPC-157 as a bulk substance from an FDA-registered facility that produces active pharmaceutical ingredients (APIs) under current Good Manufacturing Practice (cGMP) standards. The FDA requires that bulk substances for compounding come from registered API manufacturers. [11]

Before filling, patients should confirm that the pharmacy holds a Michigan Board of Pharmacy license and, for sterile preparations, has undergone a recent 797 compliance inspection.

Step 3: Understand the Remaining Gray Zone

Even with a valid prescription and a compliant pharmacy, the federal gray zone does not disappear entirely. Because BPC-157 lacks 503A bulk-substance approval from FDA, any Michigan pharmacy preparing it is taking on regulatory risk. That risk could change rapidly if FDA adds BPC-157 to a prohibited list or, alternatively, if a Category 1 designation is granted following clinical review. Patients should ask their prescriber to monitor the FDA's bulk substances evaluation page for updates. [12]

The HealthRX clinical team uses a four-point evaluation before prescribing any peptide in a federal gray zone: (1) no safer FDA-approved alternative exists for the patient's indication, (2) the compounding pharmacy holds current 503A licensure and USP 797 certification, (3) the patient has provided informed consent documenting understanding of the unapproved status, and (4) the prescriber documents ongoing monitoring of FDA enforcement signals. All four points must be satisfied before a prescription is written.

The Research Chemical Route and Why It Carries Risk

Some Michigan residents buy BPC-157 from online suppliers that label it "for research use only" or "not for human consumption." This label is a legal shield for the seller, not a protection for the buyer.

What "Research Use Only" Actually Means

The research chemical market exists because the FDA's enforcement priorities focus on sellers who market substances "for human use." Suppliers add "research use only" language to argue they are selling a laboratory reagent, not a drug. The FDA has repeatedly challenged this position when the context makes human use obvious. [13]

A person who purchases BPC-157 from a research chemical vendor and self-administers it is using an unapproved drug. They have no assurance of purity, sterility, or accurate dosing. A 2019 analysis of peptide products sold online found that a substantial proportion had incorrect concentrations or contained detectable contaminants, underscoring the risk of unregulated sourcing. [14]

State-Level Risk for Michigan Buyers

Michigan has no law that specifically criminalizes purchasing a research chemical for personal use when that chemical is not a controlled substance. But if the product is impure and causes harm, the buyer has no legal recourse against the supplier. And if a Michigan buyer imports BPC-157 from an overseas supplier, federal customs and importation rules under 21 U.S.C. 331 apply. Customs may seize the shipment, and repeated importation attempts can trigger FDA referral. [1]

What Peer-Reviewed Research Says About BPC-157 Safety and Efficacy

Legal access questions are inseparable from the clinical evidence base, because prescribers need a defensible rationale.

Tendon and Ligament Healing Data

Animal studies consistently show BPC-157 accelerates collagen synthesis and angiogenesis at injury sites. A 2010 study in the Journal of Physiology and Pharmacology (N=40 rats) found that BPC-157 significantly improved Achilles tendon transection healing compared to controls (P<0.01). [15] Those findings have been replicated in multiple rodent models, but no randomized controlled human trial has confirmed equivalent effects in people.

The absence of human RCT data is clinically significant. Prescribers in Michigan who offer BPC-157 for musculoskeletal healing are extrapolating from animal data, which is a legitimate but legally and ethically complex practice.

Gut and GI Research

BPC-157 was originally derived from gastric juice protein and has shown dose-dependent protection against NSAID-induced gastric ulcers in animal models. A 1994 paper in the Journal of Physiology (Paris) demonstrated mucosal healing acceleration at doses as low as 10 micrograms per kilogram body weight in rats. [16] No large human RCT on GI indications has been completed, though a small pilot study registered on ClinicalTrials.gov (NCT02540135) examined BPC-157 in inflammatory bowel disease and reported no serious adverse events in preliminary observations. [17]

Safety Profile: What Is Known

No human RCT has reported serious adverse events attributable to BPC-157. Case series and anecdotal reports from clinical use suggest mild injection-site reactions and transient nausea at higher doses. The absence of a safety signal in small human studies does not equal confirmed safety. The FDA's standard for approved drugs requires demonstration of both efficacy and safety across large populations, and BPC-157 has not met that bar. [1]

Monitoring for Legal Changes: The FDA Bulk Substances Process

The legal status of BPC-157 could shift within 12 to 24 months depending on FDA decisions.

How the Evaluation Process Works

The FDA evaluates nominated bulk substances through a multi-step process. A substance nominated for the 503A list is reviewed by the FDA's Pharmacy Compounding Advisory Committee (PCAC). The PCAC assesses clinical need, safety data, and whether an approved alternative exists. Substances that pass receive a Category 1 designation, allowing 503A pharmacies to compound them legally. Substances that fail receive a Category 2 designation, which prohibits their compounding. [3]

BPC-157 is currently under evaluation. A negative PCAC recommendation would effectively ban its compounding in the United States. Michigan patients currently using it through the compounding route should understand this timeline and ask their prescriber to flag any FDA decision.

What a Positive Ruling Would Change

A Category 1 designation would allow Michigan 503A pharmacies to compound BPC-157 with full federal clarity. It would not make BPC-157 FDA-approved in the traditional sense, but it would remove the primary legal uncertainty that currently surrounds it. Prescribers and patients would retain the need for a valid prescription and a licensed pharmacy.

A Direct Word on Telehealth Prescribing in Michigan

Telehealth has become the primary access point for peptide prescriptions across the United States, including Michigan. Michigan's telehealth statute, MCL 333.16285, permits licensed providers to prescribe through audio-video platforms when they have established a valid patient-provider relationship.

The Michigan Department of Licensing and Regulatory Affairs (LARA) has not issued specific guidance prohibiting telehealth prescribing of compounded peptides. [18] That silence is not permission, but it reflects the current absence of state-level enforcement targeting this practice.

HealthRX physicians licensed in Michigan conduct full medical evaluations before prescribing any compounded peptide, including BPC-157. A consultation includes review of current medications, relevant labs, and documented informed consent. Prescriptions are sent only to pharmacies whose compounding credentials HealthRX has independently verified.